Philip Morris has recently been in the news for the $820 million acquisition of Denmark-based nicotine gum maker, Fertin Pharma in order to add its various nicotine replacement therapies to its portfolio. The company delivered another strong result coupled with dividend and buyback announcements but its core cigarette and tobacco business has been slowing down in terms of revenues. However, its reduced risk products (RRPs) business continues to gain strong momentum with an increasing demand for ....
